Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Osimertinib”

283 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 283 results

Early research (Phase 1)Study completedNCT05954871
What this trial is testing

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

Who this might be right for
Colorectal CancerNon-Small Cell Lung Cancer
Genentech, Inc. 10
Early research (Phase 1)Not Yet RecruitingNCT06067776
What this trial is testing

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
Jonathan Riess 36
Large-scale testing (Phase 3)Not Yet RecruitingNCT06380348
What this trial is testing

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Who this might be right for
Local Advanced or Metastatic NSCLC
Shanghai JMT-Bio Inc. 398
Not applicableStudy completedNCT03790397
What this trial is testing

Osimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive

Who this might be right for
Non Small Cell Lung Cancer
Fundación GECP 169
Not applicableUnknownNCT05314296
What this trial is testing

Osimertinib for Russian EGFR T790M Mutation-positive NSCLC Patients Who Progressed on or After EGFR TKI Therapy

Who this might be right for
Non Small Cell Lung CancerT790MEGFR Gene Mutation
N.N. Blokhin National Medical Research Center of Oncology 70
Not applicableActive Not RecruitingNCT06376084
What this trial is testing

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell LungLung NeoplasmsRespiratory Tract Neoplasms+7 more
AstraZeneca 532
Not applicableLooking for participantsNCT04216121
What this trial is testing

LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

Who this might be right for
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Universitaire Ziekenhuizen KU Leuven 39
Testing effectiveness (Phase 2)Study completedNCT03239340
What this trial is testing

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib

Who this might be right for
EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
AstraZeneca 154
Post-approval studies (Phase 4)Study completedNCT03853551
What this trial is testing

Osimertinib Study in Indian Patients

Who this might be right for
Non Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Testing effectiveness (Phase 2)UnknownNCT02811354
What this trial is testing

Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA

Who this might be right for
Carcinoma, Non-Small-Cell Lung
National University Hospital, Singapore 108
Testing effectiveness (Phase 2)UnknownNCT04316351
What this trial is testing

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

Who this might be right for
IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy
Guangzhou Institute of Respiratory Disease 60
Large-scale testing (Phase 3)Looking for participantsNCT06970639
What this trial is testing

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Who this might be right for
NSCLC Patients With Brain Metastasis
Allist Pharmaceuticals, Inc. 380
Testing effectiveness (Phase 2)Active Not RecruitingNCT04743505
What this trial is testing

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Metastatic Non Small Cell Lung Cancer
Washington University School of Medicine 27
Very early researchStudy completedNCT03755102
What this trial is testing

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

Who this might be right for
EGFR Gene MutationLung CancerLung Cancer Metastatic
Memorial Sloan Kettering Cancer Center 17
Testing effectiveness (Phase 2)UnknownNCT04882345
What this trial is testing

Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Who this might be right for
Lung CancerEGFR Gene Mutation
Shanghai Chest Hospital 40
Large-scale testing (Phase 3)Active Not RecruitingNCT05020769
What this trial is testing

SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.

Who this might be right for
Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 14
Testing effectiveness (Phase 2)Ended earlyNCT04438902
What this trial is testing

Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment

Who this might be right for
Non Small Cell Lung Cancer
First Affiliated Hospital of Zhejiang University 3
Early research (Phase 1)Looking for participantsNCT07315113
What this trial is testing

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

Who this might be right for
EGFR Mutation Positive Non-small Cell Lung CancerEGFR Mutated Non-small Cell Lung Cancer Patients
Nuvectis Pharma, Inc. 18
Post-approval studies (Phase 4)Study completedNCT05219162
What this trial is testing

Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS).

Who this might be right for
Advanced NSCLC
AstraZeneca 182
Not applicableUnknownNCT04391283
What this trial is testing

First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

Who this might be right for
Carcinoma, Non-Small-Cell Lung
First Affiliated Hospital of Zhejiang University 500
Load More Results